Core Insights - Twist Bioscience Corporation reported a first-quarter 2026 loss of 50 cents per share, aligning with Wall Street expectations, while sales reached $103.70 million, a 17% year-over-year increase, surpassing both consensus and management guidance [1][4] Financial Performance - The adjusted EBITDA loss for the quarter was $13.4 million, an improvement from a loss of $16.3 million in the previous year [1][2] - Gross margin for the first quarter of fiscal 2026 increased to 52%, up from 48.3% a year ago [2] - The company had approximately $198 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [3] Customer and Product Metrics - Twist shipped products to approximately 2,538 customers in Q1 2026, an increase from about 2,376 customers a year ago [2] - The company shipped approximately 271,000 genes in the quarter, compared to around 205,000 genes in the same period last year [2] Future Outlook - Twist Bioscience raised its fiscal 2026 sales guidance to $435 million-$440 million, compared to the previous range of $425 million-$435 million, with expectations for revenue growth balanced across DSPS and NGS [4] - The company anticipates gross margin to remain above 52% for fiscal 2026 and aims for adjusted EBITDA breakeven in Q4 of fiscal 2026 [4] Analyst Commentary - Analysts express confidence in the long-term revenue growth trajectory of the company, highlighting its aggressive investments in multiple markets that could lead to over 20% growth [6] - The company's strategy to moderate investments while scaling into the FOTF is viewed positively, as it may broaden the appeal of the company's story if executed effectively [6][7]

Core Insights - Twist Bioscience Corporation reported a mixed performance for the fourth quarter, with a loss of 45 cents per share, slightly worse than the consensus estimate of a 43-cent loss, while sales reached $99.01 million, up 17% year over year, exceeding the consensus of $97.32 million [1][2] Financial Performance - The adjusted EBITDA loss for the fourth quarter was $7.8 million, an improvement from a loss of $17 million a year ago [1] - Gross margin for the fourth quarter increased to 51.3%, compared to 45.1% a year ago [2] Customer and Product Metrics - The company shipped products to approximately 3,800 customers in 2025, up from about 3,550 the previous year [2] - Twist shipped approximately 938,000 genes, an increase from approximately 772,000 genes a year ago [2] Future Outlook - For fiscal 2026, Twist Bioscience expects sales between $425 million and $435 million, significantly higher than the consensus of $374.69 million [3] - The guidance includes revenue expectations of approximately $194 million to $199 million from DNA Synthesis and Protein Solutions, and $231 million to $236 million from NGS Applications [3] - Gross margin is anticipated to be above 52% for fiscal 2026 [3] - For the first quarter of 2026, sales are projected to be between $100 million and $101 million, compared to the consensus of $100.34 million [3] Strategic Goals - The company aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026, entering a new growth phase [4] - CEO Emily M. Leproust emphasized the goal of maintaining gross margins above 50% and moving towards sustained profitable growth [4] Analyst Perspective - William Blair noted that shares of Twist trade at 3.9 times its calendar 2026 sales target, below the average of 6.3 times for high-growth life science tools peers [5] - Analyst Matt Larew expressed confidence in the long-term revenue growth trajectory, highlighting the company's aggressive investments in multiple markets, which could lead to over 20% growth [5] - The company’s strategy to moderate investments while aiming for adjusted EBITDA breakeven is seen as a positive move [6]